Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Functional Outcomes in Older Adults With Fragility Fractures of the Pelvis: The FFP-France Study

NCT07871084 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-12-01
Last updated
2026-10-13

Condition(s) studied

Fragility Fractures of the Pelvis (FFP)Osteoporotic Fractures

Investigational drug(s) / intervention(s)

Observational Assessment of Fragility Fractures of the Pelvis

Observational Assessment of Fragility Fractures of the Pelvis: No study-specific intervention is performed. Diagnostic and therapeutic management is determined by routine clinical practice at each participating center. Clinical, radiological, treatment, and outcome data are collected for observational purposes.

Study summary

Fragility fractures of the pelvis (FFP) are an increasingly common complication of osteoporosis in older adults and are associated with substantial morbidity, loss of independence, and mortality. Despite their clinical impact, FFP remain underdiagnosed, particularly sacral fractures, and their management varies considerably across centers.FFP-France is a French multicenter ambispective observational study designed to describe functional outcomes in adults aged 60 years and older with FFP. The primary objective is to assess functional outcome at 6 months using the Parker Mobility Score. Secondary objectives include describing clinical and radiological characteristics, diagnostic and therapeutic management, pain, autonomy, mortality, osteoporosis management, and factors associated with unfavorable functional recovery.

Eligibility

Sex
ALL
Min age
60 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥60 years. * Fragility fracture of the pelvis occurring spontaneously or following a low energy trauma. * Fracture confirmed by imaging (radiography, computed tomography, magnetic resonance imaging, bone scintigraphy, or positron emission tomography). Exclusion Criteria: * Pelvic fracture resulting from high-energy trauma. * Pathological fracture secondary to a malignant bone lesion.

Primary outcome measure(s)

  • Functional Mobility at 6 Months Assessed by the Parker Mobility Score (PMS) — 6 months after the fragility fracture of the pelvis
    Functional mobility will be assessed using the Parker Mobility Score (PMS), which evaluates the participant's ability to walk indoors, walk outdoors, and go shopping. Each item is scored from 0 to 3, resulting in a total score ranging from 0 to 9, with higher scores indicating greater mobility.

Trial sites (1)

FacilityCityRegionStatus
CHU de Nice Nice Alpes Maritimes

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07871084 on ClinicalTrials.gov ↗ ← All trials in France